Edition:
United Kingdom

CTI Biopharma Announces Outcome From End-Of-Phase-2A Meeting With FDA Regarding Pacritinib


Thursday, 18 Jul 2019 

July 18 (Reuters) - CTI Biopharma Corp ::CTI BIOPHARMA ANNOUNCES OUTCOME FROM END-OF-PHASE-2A MEETING WITH U.S. FOOD AND DRUG ADMINISTRATION (FDA) REGARDING PACRITINIB FOR TREATMENT OF MYELOFIBROSIS.CTI BIOPHARMA CORP - COMPANY PLANS TO INITIATE PHASE 3 PACIFICA STUDY IN Q3 OF 2019.CTI BIOPHARMA CORP - PLANS TO ADVANCE PACRITINIB 200 MG TWICE-DAILY (BID) DOSE TO PHASE 3 FOR PATIENTS WITH SEVERE THROMBOCYTOPENIA.CTI BIOPHARMA CORP - COMPANY EXPECTS TOPLINE SAFETY AND EFFICACY RESULTS FROM PHASE 2 PORTION OF PAC203 STUDY IN Q3 OF 2019.CTI BIOPHARMA CORP - TARGETING PRESENTATION OF PHASE 2 RESULTS FOR PAC203 STUDY AT A SCIENTIFIC CONFERENCE BEFORE END OF 2019.CTI BIOPHARMA CORP - CURRENTLY AMENDING PROTOCOL FOR ONGOING PHASE 2 PAC203 STUDY TO INCLUDE NEW PACIFICA PHASE 3 PORTION. 

Company Quote

0.6683
 --
19 Aug 2019